Generics for Betmiga (Mirabegron) are gaining market influence. Two generics for market share expanded to 19% in just one year after its launch.

The release of generics resulted in a 14% drop in the amount of outpatient prescriptions for the original over a year.

According to UBIST, a pharmaceutical market research institute on the 21st, the size of outpatient prescription market for irritable bladder treatments with Mirabegron ingredients in the second quarter was ￦17.3 billion. Compared to ￦16.5 billion in the same period last year, it increased by 5 %. The second-quarter prescription for the original Betmiga is ￦14 billion, down 14% from a year earlier.

Hanmi